Dataset Information

Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.

ABSTRACT: We sought to assess the association between common antihypertensive drugs and the risk of incident cancer in treated hypertensive patients. Using the Korean National Health Insurance Service database, the risk of cancer incidence was analyzed in patients with hypertension who were initially free of cancer and used the following antihypertensive drug classes: Angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); beta blockers (BBs); calcium channel blockers (CCBs); and diuretics. During a median follow-up of 8.6 years, there were 4513 (6.4%) overall cancer incidences from an initial 70,549 individuals taking antihypertensive drugs. ARB use was associated with a decreased risk for overall cancer in a crude model (hazard ratio (HR): 0.744, 95% confidence interval (CI): 0.696-0.794) and a fully adjusted model (HR: 0.833, 95% CI: 0.775-0.896) compared with individuals not taking ARBs. Other antihypertensive drugs, including ACEIs, CCBs, BBs, and diuretics, did not show significant associations with incident cancer overall. The long-term use of ARBs was significantly associated with a reduced risk of incident cancer over time. The users of common antihypertensive medications were not associated with an increased risk of cancer overall compared to users of other classes of antihypertensive drugs. ARB use was independently associated with a decreased risk of cancer overall compared to other antihypertensive drugs.

SUBMITTER: Cho IJ

PROVIDER: S-EPMC7918966 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.

Cho In-Jeong IJ Shin Jeong-Hun JH Jung Mi-Hyang MH Kang Chae Young CY Hwang Jinseub J Kwon Chang Hee CH Kim Woohyeun W Kim Dae-Hee DH Lee Chan Joo CJ Kang Si-Hyuck SH Lee Ju-Hee JH Kim Hack-Lyoung HL Kim Hyue Mee HM Cho Iksung I Lee Hae-Young HY Chung Wook-Jin WJ Ihm Sang-Hyun SH Kim Kwang Il KI Cho Eun Joo EJ Sohn Il-Suk IS Park Sungha S Shin Jinho J Ryu Sung Kee SK Kim Jang Young JY Kang Seok-Min SM Cho Myeong-Chan MC Pyun Wook Bum WB Sung Ki-Chul KC

Journal of clinical medicine 20210215 4

We sought to assess the association between common antihypertensive drugs and the risk of incident cancer in treated hypertensive patients. Using the Korean National Health Insurance Service database, the risk of cancer incidence was analyzed in patients with hypertension who were initially free of cancer and used the following antihypertensive drug classes: Angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); beta blockers (BBs); calcium channel blockers (CCBs ...[more]

PMID: 33671916

Similar Datasets

Project description:BackgroundPreviously studies shown a potential risk of antihypertensive medicines in relation to cancer susceptibility, which creating significant debate in the scientific community and public concern. We sought to investigate the relationship between antihypertensive medicines and cancer risk, by drug type and class.MethodsWe conducted a population-based cohort study and enrolled patients diagnosed with hypertension from community healthcare centers in Changning District, Shanghai, China. Antihypertensive drug administration were classified as five common antihypertensive drugs. The main outcomes were incidence of total cancer and by major cancer type.ResultsBetween January 2013 and December 2017, a total of 101,370 hypertensive patients were enrolled in this cohort. During a mean follow-up of 5.1 (SD 1.3) years, 4970 cancer cases were newly diagnosed in the cohort. CCBs were the most frequently used antihypertensives which were associated with a moderately increased risk of total cancer (hazard ratio, HR = 1.11, 95% CI: 1.05-1.18). The second commonly used drug ARBs were also associated with increased risk of total cancer (HR = 1.10, 95%CI: 1.03-1.17) as well as lung and thyroid cancers (HR = 1.21, 95%CI: 1.05-1.39; HR = 1.62 95%CI: 1.18-2.21, respectively). No significant association was found between cancer and other antihypertensives. Hypertensive patients who use more than one class of antihypertensives drugs had a higher risk of total cancer (HR: 1.22, 95%CI: 1.10-1.35 for two classes; HR: 1.22, 95%CI: 1.03-1.45 for three or more classes), and a possible dose-response relationship was suggested (P for trend < 0.001). The risk of thyroid cancer was higher in hypertensive patients prescribed with three or more antihypertensive classes.ConclusionsUse of ARBs or CCBs may be associated with an increased risk of total cancer. Taking more than one class of antihypertensives drugs appeared to have a higher risk for total cancer.

Dataset Information

Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.

Publications

Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets